Literature DB >> 16022912

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.

Timothy C Kennedy1, Wilbur A Franklin, Sheila A Prindiville, Robert Cook, Edward C Dempsey, Robert L Keith, Fred R Hirsch, Thomas A Merrick, Kenneth R Shroyer, Thomas L Petty, Tim Byers, Paul A Bunn, York E Miller.   

Abstract

Early stage radiographically occult lung cancer has a high cure rate, but comprises a small fraction of all lung cancer. Abnormal sputum cytology is one indication for bronchoscopy in patients with chest imaging that is not suspicious for lung cancer. While there is good evidence that sputum cytologic findings of carcinoma, carcinoma in situ or severe atypia predict high rates of diagnosis of lung cancer, less is known of the frequency in which lung cancer is diagnosed in bronchoscopies carried out for the indication of moderate sputum atypia. One small series, published in abstract form only, reported an 8% rate of diagnosis of lung cancer in subjects bronchoscoped for moderate atypia. We tested the hypothesis that moderate sputum atypia is an indicator of occult central airway cancer in a retrospective analysis of a group of high risk subjects, defined as current or former smokers with >30 pack-years tobacco smoking and airflow obstruction with moderate atypia sputum cytology. Seventy-nine such subjects with no evidence of malignancy on chest radiograph at the time bronchoscopy was scheduled underwent white light and autofluorescence bronchoscopy. Lung cancer was found in five subjects; three had invasive squamous cell carcinomas and two had carcinoma in situ. Seven additional subjects had severe dysplasia found on endobronchial biopsy. Moderate sputum atypia may be an important marker of risk for occult endobronchial malignancy in high risk subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16022912     DOI: 10.1016/j.lungcan.2005.02.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.

Authors:  Marileila Varella-Garcia; Aline P Schulte; Holly J Wolf; William J Feser; Chan Zeng; Sarah Braudrick; Xiang Yin; Fred R Hirsch; Timothy C Kennedy; Robert L Keith; Anna E Barón; Steven A Belinsky; York E Miller; Tim Byers; Wilbur A Franklin
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

2.  Detection and minimally invasive treatment of early squamous lung cancer.

Authors:  Johannes M A Daniels; Thomas G Sutedja
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

3.  Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment.

Authors:  Gregory Loewen; Nachimuthu Natarajan; Dongfeng Tan; Enriqueta Nava; Donald Klippenstein; Martin Mahoney; Michael Cummings; Mary Reid
Journal:  Thorax       Date:  2006-11-13       Impact factor: 9.139

4.  Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.

Authors:  Walter N Hittelman; Diane D Liu; Jonathan M Kurie; Reuben Lotan; Jin Soo Lee; Fadlo Khuri; Heladio Ibarguen; Rodolfo C Morice; Garrett Walsh; Jack A Roth; John Minna; Jae Y Ro; Anita Broxson; Waun Ki Hong; J Jack Lee
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

5.  2020 Innovation-Based Optimism for Lung Cancer Outcomes.

Authors:  Erin L Schenk; Tejas Patil; Jose Pacheco; Paul A Bunn
Journal:  Oncologist       Date:  2020-12-20

Review 6.  Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Eva Szabo; Jenny T Mao; Stephen Lam; Mary E Reid; Robert L Keith
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.